Undisclosed circRNA Program
Triple-negative Breast Cancer
Pre-clinicalActive
Key Facts
About CircNova
CircNova is a private, pre-clinical biotech firm founded in 2020, combining artificial intelligence and circular RNA biology to discover novel therapeutics. Its core technology, the AI NovaEngine, is claimed to be the world's first deep-learning platform capable of predicting circRNA 3D structures, aiming to accelerate drug design for challenging targets. The company, with dual locations in Detroit, Michigan and Cambridge, Massachusetts, is led by a team with experience in biotech and AI, and has secured early-stage investment from entities like Michigan Rise.
View full company profileTherapeutic Areas
Other Triple-negative Breast Cancer Drugs
| Drug | Company | Phase |
|---|---|---|
| CB-839 (Telaglenastat) | Calithera Biosciences | Phase 2 |
| RejuverSen Antibody | Centenara Labs | Pre-Clinical |
| FlowVax BreastCA | Flow Pharma | Pre-clinical |
| Radiolabeled hTAB004 (Therapeutic) | OncoTAb | Preclinical |
| AI Predictor for TNBC | PathomIQ | Development/Validation |
| TNBC Biomarker/Target Discovery | CogNano | Preclinical (Mouse Studies) |